

Featured Stocks in October's Most Attractive & Most Dangerous Model Portfolios

Recap from September's Picks

Our Most Attractive Stocks (+7.5%) outperformed the S&P 500 +2.6%) last month. Most Attractive Large Cap stock NetApp (NTAP) gained 14%. Most Attractive Small Cap stock Nova Measuring Instruments (NVMI) was up 28%. Overall, 31 out of the 40 Most Attractive stocks outperformed the S&P 500 in September.

Our Most Dangerous Stocks (+7.6%) underperformed the S&P 500 (+2.6%) as a short portfolio last month. Most Dangerous Large Cap stock MGM Resorts International (MGM) fell 10%. Most Dangerous Small Cap stock Trans World Entertainment (TWMC) fell by 18%. Overall, 11 out of the 40 Most Dangerous stocks outperformed the S&P 500 as short positions in September.

The successes of the Most Attractive and Most Dangerous stocks highlight the value of our <u>Robo-Analyst</u> technology, which helps clients fulfill the <u>fiduciary duty of care</u> when making investment recommendations¹.

13 new stocks made this month's Most Attractive list and 11 new stocks fell onto this month's Most Dangerous list. October's Most Attractive and Most Dangerous stocks were made available to members on October 3, 2017.

Our Most Attractive stocks have high and rising returns on invested capital (ROIC) and low <u>price to economic</u> <u>book value ratios</u>. Most Dangerous stocks have <u>misleading earnings</u> and long <u>growth appreciation</u> <u>periods</u> implied by their market valuations.

Most Attractive Stocks Feature for October: Cirrus Logic, Inc. (CRUS, \$55/share)

Cirrus Logic (CRUS), a manufacturer of specialized semiconductors, is the featured stock from October's <u>Most</u> <u>Attractive Stocks</u>.

Over the past decade, revenue has grown 24% compounded annually while after-tax profits (NOPAT) have grown 36% compounded annually. Momentum has shown no signs of waning in more recent years. Since yearend 2014, revenue has grown 29% compounded annually while NOPAT has grown 32% compounded annually. Profit margins also continue to improve. CRUS' NOPAT margin has risen from 6% in 2007 to 17% over the trailing twelve months (TTM). The firm's current 18% ROIC (TTM) is top-quintile among our <u>coverage universe</u>.




Figure 1: CRUS 10-Year Revenues and NOPAT Margin

¹ Ernst & Young's recent white paper, "<u>Getting ROIC Right</u>", proves the superiority of our research and analytics.

Page 1 of 5

Important Disclosure Information is contained on the last page of this report. The recipient of this report is directed to read these disclosures.



Priced for Permanent Profit Decline

At its current price of \$55/share, CRUS has a price-to-economic book value (<u>PEBV</u>) ratio of 0.9. This ratio means the market expects CRUS' NOPAT to permanently decline by 10% from current levels. This expectation seems overly pessimistic for a firm that has generated 36% compound annual NOPAT growth over the past ten years and has shown no signs of losing momentum.

If CRUS can operate at its five-year average NOPAT margin of 14% (vs. 17% TTM), grow revenue 5% compounded annually, and grow NOPAT by 4% compounded annually over the next decade, the stock is worth \$68/share today – a 25% upside. In a more optimistic scenario of <u>6% compound annual NOPAT growth over the next decade</u>, the stock is worth \$79/share today – a 44% upside.

Auditable Impact of Footnotes and Forensic Accounting Adjustments²

Our <u>Robo-Analyst technology</u> enables us to perform forensic accounting with scale and provide the <u>research</u> <u>needed</u> to fulfill fiduciary duties. In order to derive the <u>true recurring cash flows</u>, an accurate <u>invested capital</u>, and an accurate shareholder value, we made the following adjustments to Cirrus Logic's (CRUS) 2017 10-K:

Income Statement: we made \$85 million of adjustments, with a net effect of removing \$13 million in nonoperating income (<1% of revenue). We removed \$49 million in <u>non-operating income</u> and \$36 million in <u>non-operating expenses</u>. You can see all the adjustments made to CRUS's income statement <u>here</u>.

Balance Sheet: we made \$986 million of adjustments to calculate invested capital with a net increase of \$116 million. One of the largest adjustments was \$39 million due to <u>asset write-downs</u>. This adjustment represented 37% of reported net assets. You can see all the adjustments made to CRUS's balance sheet <u>here</u>.

Valuation: we made \$346 million of adjustments with a net effect of increasing shareholder value by \$116 million. The largest adjustment to shareholder value was \$67 million in off-balance sheet <u>operating leases</u>. This adjustment represents 2% of CRUS's market cap.

Most Dangerous Stocks Feature: AstraZeneca PLC (AZN, \$35/share)


AstraZeneca PLC (AZN), the 10th largest pharmaceutical firm by market cap, is the featured stock from October's <u>Most Dangerous Stocks</u>.

Over the past decade, AZN's revenues have declined 3% compounded annually while after-tax profits (<u>NOPAT</u>) have declined 9% compounded annually. The impact of shrinking revenues has been magnified by a significant drop in NOPAT margin from 22% in 2007 to 12% TTM. Since year-end 2014, the revenue decline has accelerated to 6% compounded annually. NOPAT has remained flat, however, due to a modest rebound in NOPAT margin from the 10% low in 2014. AZN's ROIC has declined from 27% in 2007 to 5% TTM.

² Ernst & Young's recent white paper, "Getting ROIC Right", proves the superiority of our research and analytics.



Figure 2: AZN 10-Year NOPAT and ROIC



AZN Presents Significant Valuation Risk

At the end of 2012, AZN's stock traded at a 0.4 PEBV ratio, which meant the market was (accurately) pricing in a 60% decline in NOPAT. Since that time, AZN's NOPAT (TTM) is down 64%. However, AZN's stock price is 46% higher than the end of 2012. AZN now trades at a PEBV ratio of 3.2. This ratio means the market expects AZN's NOPAT to grow to 320% of current levels, or roughly \$8.6 billion vs. \$2.7 billion TTM. This level of optimism seems unwarranted in light of AZN's financial performance over the past decade and TTM period.

To justify its current price of \$35/share, AZN must immediately improve NOPAT margins to the ten-year average of 20% (compared to 12% TTM), grow revenue 3% compounded annually, and grow NOPAT 7% compounded annually over the next decade. Even if AZN improves NOPAT margin to 15%, grows revenue by 3% compounded annually, and grows NOPAT by 4% compounded annually over the next decade, the stock is worth only \$23/share today – 34% downside.

Impacts of Footnotes Adjustments and Forensic Accounting³

Our <u>Robo-Analyst technology</u> enables us to perform forensic accounting with scale and provide the <u>research</u> <u>needed</u> to fulfill fiduciary duties. In order to derive the <u>true recurring cash flows</u>, an accurate <u>invested capital</u>, and an accurate shareholder value, we made the following adjustments to AstraZeneca PLC's 2016 10-K:

Income Statement: we made \$5.9 billion of adjustments, with a net effect of removing \$154 million in nonoperating income (6% revenue). We removed \$3.0 billion in <u>non-operating income</u> and \$2.9 billion in <u>non-operating expenses</u>. You can see all the adjustments made to AZN's income statement <u>here</u>.

Balance Sheet: we made \$17.5 billion of adjustments to calculate invested capital with a net increase of \$1.2 billion. One of the largest adjustments was \$6.7 billion due to <u>asset write-downs</u>. This adjustment represented 14% of reported net assets. You can see all the adjustments made to AZN's balance sheet <u>here</u>.

Valuation: we made \$28 billion of adjustments with a net effect of decreasing shareholder value by \$1.2 billion. Aside from <u>adjusted total debt</u> of \$18 billion, the largest adjustment to shareholder value was \$2.8 billion in <u>deferred tax liabilities</u>. This adjustment represents 3% of AZN's market cap.

This article originally published on October 12, 2017.

Disclosure: David Trainer, Kyle Guske II, and Kenneth James receive no compensation to write about any specific stock, style, or theme.

Follow us on <u>Twitter</u>, <u>Facebook</u>, <u>LinkedIn</u>, and <u>StockTwits</u> for real-time alerts on all our research.

³ Ernst & Young's recent white paper, "Getting ROIC Right", proves the superiority of our research and analytics.



New Constructs[®] - Research to Fulfill the Fiduciary Duty of Care

Ratings & screeners on 3000 stocks, 450 ETFs and 7000 mutual funds help you make prudent investment decisions.

New Constructs leverages the latest in machine learning to analyze structured and unstructured financial data with unrivaled speed and accuracy. The firm's forensic accounting experts work alongside engineers to develop proprietary NLP libraries and financial models. Our investment ratings are based on the best fundamental data in the business for stocks, ETFs and mutual funds. Clients include many of the top hedge funds, mutual funds and wealth management firms. David Trainer, the firm's CEO, is regularly featured in the media as a thought leader on the fiduciary duty of care, earnings quality, valuation and investment strategy.

To fulfill the Duty of Care, research should be:

- 1. **Comprehensive** All relevant publicly-available (e.g. 10-Ks and 10-Qs) information has been diligently reviewed, including footnotes and the management discussion & analysis (MD&A).
- 2. **Un-conflicted** Clients deserve unbiased research.
- 3. **Transparent** Advisors should be able to show how the analysis was performed and the data behind it.
- 4. **Relevant** Empirical evidence must provide <u>tangible, quantifiable correlation</u> to stock, ETF or mutual fund performance.

Value Investing 2.0: Diligence Matters: Technology is Key to Value Investing With Scale

Accounting data is only the beginning of fundamental research. It must be translated into economic earnings to truly understand profitability and valuation. This translation requires deep analysis of footnotes and the MD&A, a process that our <u>robo-analyst technology</u> empowers us to perform for thousands of stocks, ETFs and mutual funds.



DISCLOSURES

New Constructs®, LLC (together with any subsidiaries and/or affiliates, "New Constructs") is an independent organization with no management ties to the companies it covers. None of the members of New Constructs' management team or the management team of any New Constructs' affiliate holds a seat on the Board of Directors of any of the companies New Constructs covers. New Constructs does not perform any investment or merchant banking functions and does not operate a trading desk.

New Constructs' Stock Ownership Policy prevents any of its employees or managers from engaging in Insider Trading and restricts any trading whereby an employee may exploit inside information regarding our stock research. In addition, employees and managers of the company are bound by a code of ethics that restricts them from purchasing or selling a security that they know or should have known was under consideration for inclusion in a New Constructs report nor may they purchase or sell a security for the first 15 days after New Constructs issues a report on that security.

DISCLAIMERS

The information and opinions presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or solicitation of an offer to buy or sell securities or other financial instruments. New Constructs has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor and nothing in this report constitutes investment, legal, accounting or tax advice. This report includes general information that does not take into account your individual circumstance, financial situation or needs, nor does it represent a personal recommendation to you. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about any such investments or investment services.

Information and opinions presented in this report have been obtained or derived from sources believed by New Constructs to be reliable, but New Constructs makes no representation as to their accuracy, authority, usefulness, reliability, timeliness or completeness. New Constructs accepts no liability for loss arising from the use of the information presented in this report, and New Constructs makes no warranty as to results that may be obtained from the information presented in this report. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information and opinions contained in this report reflect a judgment at its original date of publication by New Constructs and are subject to change without notice. New Constructs may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and New Constructs is under no obligation to insure that such other reports are brought to the attention of any recipient of this report.

New Constructs' reports are intended for distribution to its professional and institutional investor customers. Recipients who are not professionals or institutional investor customers of New Constructs should seek the advice of their independent financial advisor prior to making any investment decision or for any necessary explanation of its contents.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would be subject New Constructs to any registration or licensing requirement within such jurisdiction.

This report may provide the addresses of websites. Except to the extent to which the report refers to New Constructs own website material, New Constructs has not reviewed the linked site and takes no responsibility for the content therein. Such address or hyperlink (including addresses or hyperlinks to New Constructs own website material) is provided solely for your convenience and the information and content of the linked site do not in any way form part of this report. Accessing such websites or following such hyperlink through this report shall be at your own risk.

All material in this report is the property of, and under copyright, of New Constructs. None of the contents, nor any copy of it, may be altered in any way, copied, or distributed or transmitted to any other party without the prior express written consent of New Constructs. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of New Constructs.

Copyright New Constructs, LLC 2003 through the present date. All rights reserved.